MHLW Approves Additional Indications For Sanofi’s Taxotere And Designates Pfizer’s Selzentry An Orphan Drug
This article was originally published in PharmAsia News
The second division on drugs of the Ministry of Health, Labor and Welfare's Pharmaceutical and Food Sanitation Council approved July 31 additional indications of treating prostate cancer to Sanofi Aventis' Taxotere (docetaxel), mycobacterium avium complex to Taisho Pharmaceutical's Clarith (clarithromycin)and Abbott Japan's Klacid (clarithromycin). The committee also designated Pfizer's HIV drug Selzentry (maraviroc) an orphan drug. (Click here for more - Japanese language
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.